U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07551037) titled 'Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy' on April 20.
Brief Summary: Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While approximately 70% of patients achieve complete remission (CR) with induction chemotherapy, traditional consolidation therapy (predominantly high-dose cytarabine) has a persistently high recurrence rate - nearly 30% at 1 year for low-risk groups and 80% for high-risk groups - with a long-term survival rate <40%. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improves survival but is limited by donor matching and patien...